TAM Stock Screener – Stocks Appearing In Cohen, Griffin, Simons Portfolios

Johnny HopkinsStock Screener2 Comments

Part of the weekly research here at The Acquirer’s Multiple features some of the top picks from our Stock Screeners and some top investors who are holding these same picks in their portfolios. Investors such as Warren Buffett, Joel Greenblatt, Carl Icahn, Jim Simons, Prem Watsa, Jeremy Grantham, Seth Klarman, Ray Dalio, and Howard Marks. The top investor data is provided from their latest 13F’s. This week we’ll take a look at:

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX)

Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising drug targets. Lexicon then designs and develops drugs for these targets, which cover a broad spectrum of therapeutic areas. Following a restructuring in January 2014, Lexicon focused efforts on two drugs: sotagliflozin in diabetes, which is partnered with Sanofi, and Xermelo (telotristat etiprate) in carcinoid syndrome, which is partnered with Ipsen outside the U.S. Early-stage programs include SGLT1 inhibitor LX2761 and neuropathic pain drug LX9211.

A quick look at the price chart below for Lexicon Pharmaceuticals shows us that the stock is down 40% in the past twelve months. We currently have the stock trading on an Acquirer’s Multiple of 1.80 which means that it remains undervalued.

(Source: Morningstar)

Superinvestors who currently hold positions in Lexicon Pharmaceuticals include:

Israel Englander – 1,220,629 total shares

Jim Simons – 665,379 total shares

Steve Cohen – 528,100 total shares

Ken Griffin – 204,968 total shares

Michael Gelband – 136,840 total shares

Cliff Asness – 43,810 total shares

For more articles like this, check out our recent articles here.

FREE Stock Screener

Don’t forget to check out our FREE Large Cap 1000 – Stock Screener, here at The Acquirer’s Multiple:

unlimited

2 Comments on “TAM Stock Screener – Stocks Appearing In Cohen, Griffin, Simons Portfolios”

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.